Florence Chaput1, Radgonde Amer2, Edoardo Baglivo3, Valerie Touitou4, Alexandra Kozyreff5, Dominique Bron6, Bahram Bodaghi4, Phuc LeHoang4, Chris Bergstrom7, Hans E Grossniklaus7, Chi-Chao Chan8, Jacob Pe'er2, Laure E Caspers1. 1. a Centre Hospitalo-Universitaire (CHU) Saint-Pierre, Université Libre de Bruxelles , Brussels , Belgium. 2. b Hadassah-Hebrew University Medical Centre , Jerusalem , Israel. 3. c Hôpital Universitaire Genève , Geneva , Switzerland. 4. d Hôpital Universitaire La Pitié Salpêtrière , Paris , France. 5. e Clinique St Luc, Université Catholique de Louvain , Brussels , Belgium. 6. f Institut Bordet, Université Libre de Bruxelles , Brussels , Belgium. 7. g Department of Ophthalmology , Emory University School of Medicine , Atlanta , Georgia , USA. 8. h National Institute of Heath, NEI, Laboratory of Pathology , Bethesda , Maryland , USA.
Abstract
PURPOSE: To report on the clinical data of seven patients with T-cell intraocular lymphoma (IOL). METHODS: Retrospective case series. RESULTS: Seven immunocompetent patients, 12 eyes, 6 women, with T-cell-IOL were included from five countries. Mean age was 53.5 years (range: 25-82). Four patients had systemic-ocular lymphoma, two had CNS-ocular lymphoma, and one had systemic-CNS- ocular lymphoma. Vitritis was the most frequent clinical sign, followed by anterior uveitis and serous retinal detachment. Cytopathologic examination was performed on all ocular specimens (vitreous in six and iris mass biopsy in one patient). Adjunctive diagnostic procedures included immunohistochemistry, molecular tests, and cytokine profiling of vitreous samples. Treatment modalities included systemic chemotherapy (five patients), intravitreal methotrexate (three patients), globe radiotherapy, and intrathecal chemotherapy. Mean survival from diagnosis was 21.7 months (range: 2-69). Two patients are still alive. CONCLUSIONS: T-cell IOL has variable clinical manifestations and prognosis. Systemic involvement, SRD, and vitreoretinal involvement were frequently observed.
PURPOSE: To report on the clinical data of seven patients with T-cell intraocular lymphoma (IOL). METHODS: Retrospective case series. RESULTS: Seven immunocompetent patients, 12 eyes, 6 women, with T-cell-IOL were included from five countries. Mean age was 53.5 years (range: 25-82). Four patients had systemic-ocular lymphoma, two had CNS-ocular lymphoma, and one had systemic-CNS- ocular lymphoma. Vitritis was the most frequent clinical sign, followed by anterior uveitis and serous retinal detachment. Cytopathologic examination was performed on all ocular specimens (vitreous in six and iris mass biopsy in one patient). Adjunctive diagnostic procedures included immunohistochemistry, molecular tests, and cytokine profiling of vitreous samples. Treatment modalities included systemic chemotherapy (five patients), intravitreal methotrexate (three patients), globe radiotherapy, and intrathecal chemotherapy. Mean survival from diagnosis was 21.7 months (range: 2-69). Two patients are still alive. CONCLUSIONS: T-cell IOL has variable clinical manifestations and prognosis. Systemic involvement, SRD, and vitreoretinal involvement were frequently observed.
Authors: Victor Llorenç; Carla Fuster; Carmen Alba-Linero; Aina Moll-Udina; Alba Serrano; Manel Solé; Maite Sainz de la Maza; Iban Aldecoa; Alfredo Adán Journal: J Ophthalmol Date: 2019-10-16 Impact factor: 1.909
Authors: Rodolfo Mastropasqua; Emma Di Carlo; Carlo Sorrentino; Cesare Mariotti; Lyndon da Cruz Journal: J Clin Med Date: 2019-10-19 Impact factor: 4.241
Authors: Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox Journal: Br J Haematol Date: 2022-03-16 Impact factor: 8.615